West Nile-Innovator DNA is the first DNA vaccine of its kind and is the first animal DNA vaccine to by fully licensed by the USDA.1 Unlike conventional vaccines, which rely on the foreign proteins derived from disease-causing agents, West Nile-Innovator DNA uses purified DNA plasmids to stimulate an immune response. West Nile-Innovator DNA contains no live or killed viruses, no live vector or viral proteins, and there is no risk of reversion to virulence.
VACCINE ADMINISTRATION
For the vaccination of healthy horses 8 months and older with a 2 mL dose by intramuscular injection using aseptic technique. Administer a second 2 mL dose two to four weeks after the first dose. Revaccinate annually with one 2 mL dose.
West Nile-Innovator DNA: The First Ever DNA Vaccine In Veterinary Medicine Detailer
West Nile-Innovator DNA One-Page Summary
West-Nile Innovator® DNA Product Label
back to top
INNOVATION TO LEAD
For the first time, West Nile-Innovator DNA puts a revolutionary method of vaccination at your disposal. Developed by the research scientists at the U.S. Centers for Disease Control and Prevention (CDC), it is the first vaccine of its kind in the country fully licensed by USDA.1
back to top
SAFETY TO TRUST
Greater than 99 percent reaction-free when administered intramuscularly to 645 male and female horses of various breeds and ages, including some horses as young as 2 months of age (based on field safety studies).2
back to top
DURATION TO DEPEND ON
West Nile-Innovator DNA demonstrated 12-month duration of immunity in 8- to 9-month-old horses and older, based on viremia.2
back to top
EFFICACY TO RELY ON
West Nile-Innovator DNA administered IM has been shown in challenge studies to be efficacious based on viremia.2 It contains MetaStim®, which has demonstrated antibody and CMI responses.3
back to top
FLEXIBILITY TO APPLY TODAY
Circulating passive maternal antibodies can render some traditional vaccines ineffective. Maternal antibody interference trials using foals as young as 3 weeks of age show foals developed amnestic antibody responses against West Nile virus after vaccination—even in the presence of high maternal antibody titers.4
back to top
1. USDA-APHIS-VS-CVB. Veterinary Biological Licenses and Permittees June 2008.
2. Data on file. Fort Dodge Animal Health.
3. Davis, EG, Y Zhang, J Tuttle, K Hankins and MJ Wilderson. “Investigation of Antigen Specific Lymphocyte Responses in Healthy Horses Vaccinated with an Inactivated West Nile Virus Vaccine.” Western Veterinary Conference. 2006.
4. Chiang YW, PhD; Jennen CM, Holt TM et al. Demonstration of Efficacy of a West Nile Virus DNA Vaccine in Foals. Proc. AAEP Annual Meeting. 20005/51:183-190.
